References

1.      Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al[2005]. Epidemiology and outcome of zygomycosis: A review of 929 reported cases. Clin Infect Dis. ;41:634–53. [PubMed]

2.      Gamaletsou MN¹, Sipsas NV, Roilides E, Walsh TJ[2012].Rhino-orbital-cerebral mucormycosis.Current Infectious Disease Report.  Aug;14(4):423-34. doi: 10.1007/s11908-012-0272-6.

3.      Bhansali A, Bhadada S, Sharma A, et al[2004]. Presentation and outcome of rhino-orbital-cerebral mucormycosis in patients with diabetes. Postgrad Med J. 2004;80(949):670–674. doi:10.1136/pgmj.2003.016030. [PMC free article] [PubMed]

4.      Ferguson BJ¹, Mitchell TG, Moon R,  Camporesi EM, Farmer J[1988]. Adjun-ctive hyperbaric oxygen for treatment of rhinocerebral mucormy-cosis. 1988 May-Jun;10(3):551-9. [Pub Med].

5.      R.A. Yohai, J.D. Bullock, A.A. Aziz, R.J. Markert[1994]Survival factors in rhino-orbital-cerebral mucormycosis.Surv. Ophthalmol., 39 (1) (1994), pp. 3–22

6.      E.J.C. Goldstein, B. Spellberg, T.J. Walsh, D.P. Kontoyiannis, J. Edwards Jr, A. Ibrahim[2009]Recent advances in the management of mucormycosis: from bench to bedsideClin. Infect. Dis., 48 (12) (20.09), pp. 1743–1751.

7.      D.E. Adler, T.H. Milhorat, J.I. Miller[1998]Treatment of rhinocerebral mucormycosis with intravenous interst-itial, and cerebrospinal fluid administration of amphotericin B: case report Neurosurgery, 42 (3) (1998), pp. 644–648.

Corresponding Author